Twist Bioscience

Q3 FY2026 EarningsQ3 FY26 results beat consensus on both top and bottom lines: revenue $118.4M vs. $114.5M expected, and gross margin reached 52.8% vs. 52.0% consensus. While GAAP EPS of -$0.56 was slightly lower than the -$0.48 consensus due to higher SG&A, the company raised FY26 revenue guidance to $456M-$457M and reiterated its target for Q4 FY26 Adjusted EBITDA breakeven. DNA Synthesis and Protein Solutions (DSPS) was the primary growth driver, increasing 39% YoY.